Background In the past two decades, subanaesthetic doses of ketamine have been
demonstrated to have rapid and sustained antidepressant effects, and accumulating …

Depression is the third leading cause of disability in the world. Depressive symptoms may
be reduced within several weeks after the start of conventional antidepressants, but …

Objective: Ketamine may reduce suicidal ideation in treatment-resistant depression. But it is
not known how quickly this occurs and how long it persists. We undertook a systematic …

Objective: The authors conducted a systematic review and meta-analysis of ketamine and
other N-methyl-d-aspartate (NMDA) receptor antagonists in the treatment of major …

Background Racemic ketamine and esketamine have demonstrated rapid antidepressant
effects. We aimed to review the efficacy and safety of racemic and esketamine for …

Clinical and preclinical studies suggest that dysfunction of the glutamatergic system is
implicated in mood disorders such as major depressive disorder and bipolar depression. In …

Mood disorders such as major depressive disorder and bipolar disorder are chronic and
recurrent illnesses that cause significant disability and affect approximately 350 million …

Background Many studies have recently been conducted to assess the antidepressant
efficacy of glutamate modification in mood disorders. This is an update of a review first …

The feasibility of intravenous ketamine administration during the perioperative period of
cesarean section to prevent postpartum depression (PPD) has not been determined by meta …

Major depressive disorder (MDD) is a disabling disease associated with profound functional
impairment. Cognitive deficits, increasingly recognised as a core feature of MDD, reduce …